Loading...

We've got a brand new version of Simply Wall St! Try it out

Portage Biotech

CNSX:PBT.U
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PBT.U
CNSX
$109M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Portage Biotech, Inc., a pharmaceutical company, identifies, finances, and develops early-to-mid stage products. More info.


Add to Portfolio Compare Print
PBT.U Share Price and Events
7 Day Returns
0%
CNSX:PBT.U
0.6%
CA Biotechs
1.3%
CA Market
1 Year Returns
-
CNSX:PBT.U
-70.7%
CA Biotechs
-0.1%
CA Market
PBT.U Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Portage Biotech (PBT.U) 0% 0% 0% - - -
CA Biotechs 0.6% 8% -1.3% -70.7% -29.1% 28.7%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on PBT.U.
  • No trading data on PBT.U.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Portage Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Portage Biotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Portage Biotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Portage Biotech. This is due to cash flow or dividend data being unavailable. The share price is CA$0.09.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Portage Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Portage Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:PBT.U PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings () in CAD Not available
OTCPK:PTGE.F Share Price ** OTCPK (2019-08-06) in USD $0.1
North America Biotechs Industry PE Ratio Median Figure of 39 Publicly-Listed Biotechs Companies 19.07x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Portage Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Portage Biotech, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Portage Biotech's expected growth come at a high price?
Raw Data
CNSX:PBT.U PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Biotechs Industry PEG Ratio Median Figure of 32 Publicly-Listed Biotechs Companies 0.71x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Portage Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Portage Biotech's assets?
Raw Data
CNSX:PBT.U PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings () in CAD Not available
OTCPK:PTGE.F Share Price * OTCPK (2019-08-06) in USD $0.1
Canada Biotechs Industry PB Ratio Median Figure of 32 Publicly-Listed Biotechs Companies 4.13x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x

* Primary Listing of Portage Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Examine Portage Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Portage Biotech's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Portage Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Portage Biotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Portage Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Portage Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Portage Biotech expected to grow at an attractive rate?
  • Unable to compare Portage Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Portage Biotech's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Portage Biotech's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:PBT.U Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.5%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 46.2%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:PBT.U Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings () See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Portage Biotech is high growth as no earnings estimate data is available.
  • Unable to determine if Portage Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:PBT.U Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings () See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Portage Biotech Company Filings, last reported , and in Trailing twelve months (TTM) annual period rather than quarterly.

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Portage Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Portage Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Portage Biotech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Portage Biotech's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Portage Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Portage Biotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Portage Biotech performed over the past 5 years?

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Portage Biotech has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.

Show me the analysis anyway

  • No data on Portage Biotech's last earnings update.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Portage Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if Portage Biotech's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Portage Biotech's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare Portage Biotech's 1-year growth to the North America Biotechs industry average as past earnings data has not been reported.
Earnings and Revenue History
Portage Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Portage Biotech Company Filings, last reported , and in Trailing twelve months (TTM) annual period rather than quarterly.

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if Portage Biotech has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if Portage Biotech has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if Portage Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.

Next steps:

  1. Examine Portage Biotech'sPortage Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Past financial records are usually unavailable for companies that have just been established or recently publicly listed, which makes them inherently riskier. Take a look at a list of well-established companies here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Past performance checks
We assess Portage Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Portage Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Portage Biotech's financial health and their level of debt?

In this section we usually analyse Portage Biotech's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Portage Biotech has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.

Show me the analysis anyway

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Portage Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as Portage Biotech has not reported sufficient balance sheet data.
  • Unable to establish if Portage Biotech's long term commitments exceed its cash and other short term assets as Portage Biotech has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of Portage Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if Portage Biotech has a high level of physical assets or inventory without balance sheet data.
  • Portage Biotech has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Portage Biotech Company Filings, last reported .

  • Portage Biotech has no debt.
  • Portage Biotech has not taken on any debt in the past 5 years.
  • Portage Biotech has no debt, it does not need to be covered by operating cash flow.
  • Portage Biotech has no debt, therefore coverage of interest payments is not a concern.

Next steps:

  1. Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. Portage Biotech's cash and debt levels may be found in its annual reports archived here.
  2. Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Portage Biotech's financial data was last updated here.
  3. Companies with strong financial health are considered a less risky investment. Discover these stocks here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Financial health checks
We assess Portage Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Portage Biotech has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Portage Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Portage Biotech dividends.
If you bought CA$2,000 of Portage Biotech shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Portage Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Portage Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:PBT.U Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 58 Stocks 2.1%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Portage Biotech has not reported any payouts.
  • Unable to verify if Portage Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Portage Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Portage Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Portage Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Portage Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Portage Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Portage Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ian Walters
TENURE AS CEO 0.3 years
CEO Bio

Dr. Ian B. Walters, M.D., M.B.A., has been Chief Executive Officer of Portage Biotech Inc. since May 6, 2019 and serves as its Director. Dr. Walters Founded SalvaRx (LON: SALV) in 2015. Dr. Walters Founded iOx Therapeutics and serves as its and Chief Executive Officer. He serves as Chairman of The Board of Stimunity SAS. He is the Chairman of the Board of RIFT Biotherapeutics Inc. and has been its Director since March 2017. He is Entrepreneur in Residence at Medqiventures. He is an experienced life science entrepreneur who has helped found and launched several life science companies. He also serves as a part time Chief Medical Officer for Intensity Therapeutics. He was an Independent Director at Portage Biotech Inc. since August 1, 2016. Dr. Walters has led drug development teams in several therapeutic areas and contributed to bringing 4 blockbuster products to market, including Opdivo®, Yervoy®, and Velcade®. Dr. Walters worked at Bristol-Myers Squibb (BMS), where he managed physicians overseeing the international development of more than 8 oncology compounds as well as biomarker and companion diagnostic work. He also was a core member of BMS's Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions and clinical collaborations. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. He has over 20 year career, he demonstrated both leadership and expertise in drug development, including the advancement of multiple cancer compounds from research stages through approval. His previous positions include drug development and business roles at PDL BioPharma, Inc., Millenium Pharmaceuticals, Inc., and Sorrento Therapeutics, Inc. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of the University of Pennsylvania.

CEO Compensation
  • Insufficient data for Ian to compare compensation growth.
  • Insufficient data for Ian to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Ian Walters

TITLE
CEO & Director
TENURE
0.3 yrs

Kam Shah

TITLE
CFO & Director
AGE
68
Board of Directors Tenure

Average tenure and age of the Portage Biotech board of directors in years:

6.3
Average Tenure
63
Average Age
  • The tenure for the Portage Biotech board of directors is about average.
Board of Directors

Greg Bailey

TITLE
Chairman
AGE
63

Ian Walters

TITLE
CEO & Director
TENURE
3.1 yrs

Kam Shah

TITLE
CFO & Director
AGE
68
TENURE
20.7 yrs

Declan Doogan

TITLE
Independent Director
AGE
67
TENURE
6.3 yrs

Jim Mellon

TITLE
Director
AGE
62
TENURE
6.3 yrs

Steve Mintz

TITLE
Director
AGE
53
TENURE
3.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Portage Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Portage Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Portage Biotech, Inc., a pharmaceutical company, identifies, finances, and develops early-to-mid stage products. It owns 52% interest in Biohaven Pharmaceuticals, a company that is developing glutamatergic therapies for affective disorders and other indications; and owns Portage Pharmaceuticals Limited, which is developing a cell penetrating peptide platform; and also has a minority investment in Sentien Biotechnology. Portage Biotech, Inc. is based in Toronto, Canada.

Details
Name: Portage Biotech Inc.
PBT.U
Exchange: CNSX
Founded:
$144,478,633
1,089,409,928
Website: http://www.portagebiotech.com
Address: Portage Biotech Inc.
47 Avenue Road,
Suite 200,
Toronto,
Ontario, M5R 2G3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK PTGE.F Common Shares Pink Sheets LLC US USD 09. Jan 2019
CNSX PBT.U Common Shares Canadian National Stock Exchange CA CAD 09. Jan 2019
Number of employees
Current staff
Staff numbers
0
Portage Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:50
End of day share price update: 2019/08/06 00:00
Last earnings filing: N/A
Last earnings reported: N/A
Last annual earnings reported: N/A


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.